PharmacoEconomics & Outcomes News

, Volume 781, Issue 1, pp 26–26 | Cite as

Pembrolizumab cost effective for metastatic NSCLC in USA

Clinical study


  1. Huang M, et al. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. PharmacoEconomics : 15 Jun 2017. Available from: URL:

Copyright information

© Springer International Publishing AG  2017

Personalised recommendations